Sterling to Manufacture GNX102-ADC for Planned Phase 1 Clinical Program NEW TAIPEI CITY, Taiwan, Nov. 12, 2024 /PRNewswire/ — GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.